The expression of ETV6/CBFA2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivo-Reference-Cited by-同舟云学术

The expression of ETV6/CBFA2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivo

Published:2001-10 Issue:2 Volume:130 Page:93-104
ISSN:0165-4608
Container-title:Cancer Genetics and Cytogenetics
language:en
Short-container-title:Cancer Genetics and Cytogenetics

Author:

Andreasson Patrik,Schwaller Juerg,Anastasiadou Ema,Aster Jon,Gilliland D.Gary

Publisher

Elsevier BV

Subject

Cancer Research,Genetics,Molecular Biology

Reference90 articles.

1. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials;Borkhardt;Blood,1997

2. TEL gene rearrangement in acute lymphoblastic leukemia;Rubnitz;J Clin Oncol,1997

3. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia;McLean;Blood,1996

4. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pedriatic ALL and defines a subgroup of patients with an excellent prognosis;Shurtleff;Leukemia,1995

5. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia;Golub;Proc Natl Acad Sci USA,1995

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lessons from mouse models in the impact of risk factors on the genesis of childhood B-cell leukemia;Frontiers in Immunology;2023-10-12

2. Animal Models of Lymphoid Malignancies;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

3. Molecular Characteristics and Clinical Significance of Acute B-Cell Acute Lymphoblastic Leukemia in Children;Advances in Clinical Medicine;2023

4. Revisiting the concept of childhood preleukemia;Trends in Cancer;2022-11

5. Functional, structural, and molecular characterizations of the leukemogenic driver MEF2D-HNRNPUL1 fusion;Blood;2022-09-22